Biotechs to Benefit from $2B Government Ebola Contracts

Source: Bloomberg

Nov 11, 2014

Bloomberg

Multiple drugmakers involved in Ebola treatment will potentially share in $2B worth of what will likely be no-bid contract awards, as part of the $6.2 billion in emergency funding Obama asked for last week.

Several drugmakers -- including Mapp Biopharmaceutical, Johnson & Johnson, Emergent Biosolutions, NewLink Genetics and Novavax -- are currently working on vaccines and/or drugs that target the infection.

To date, there is limited public access to information pertaining to which companies have received Ebola-specific funding from the U.S. government. Congress has previously approved $838 million toward Ebola relief efforts, of which $77 million has been awarded in contracts so far this year.

Read the Bloomberg press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments